The effect of glucocorticosteroid administration on fetal movements and biophysical profile scores in normal pregnancies.
OBJECTIVE
To evaluate and quantify the effect of glucocorticosteroid administration on fetal movements and biophysical profile scores.


METHODS
Eighteen women at 32-34 weeks' gestation were enrolled. Inclusion criterion was an uncomplicated singleton pregnancy not considered to be at high risk. Patients participated for 3 consecutive days. On day 1, the patients underwent a baseline biophysical profile including a non-stress test followed by a 12-mg betamethasone intramuscular injection. On day 2, the patients received a non-stress test and a second dose of betamethasone. On day 3, a biophysical profile with non-stress test was performed. Maternal counts of fetal kicks were also recorded before, during and after the study period. Each test was conducted at approximately the same time of day to control for diurnal variation. Comparison was made between pre-betamethasone biophysical profile scores and fetal movement and post-betamethasone biophysical profile scores and fetal movement.


RESULTS
Biophysical profile scores were reduced in 28% of the study population after betamethasone administration (p < 0.05). Amniotic fluid index on day 3 was decreased from baseline in 72% of patients after betamethasone administration (p < 0.05). Forty-four per cent of patients reported a decrease in fetal movement. Of these patients, 87% had a decreased amniotic fluid index when compared to baseline (p < 0.05).


CONCLUSIONS
Fetal movements and breathing motion were decreased after glucocorticosteroid administration, as evidenced by biophysical profile scores and kick counts. The decrease in the amniotic fluid index observed after glucocorticosteroid administration may have been the result of decreased fetal breathing and, therefore, decreased efflux of alveolar fluid into the amniotic sac.
Jackson
J R
JR
Department of Obstetrics and Gynecology and the E. Kenneth Hatton MD Institute for Research and Education, Good Samaritan Hospital, Cincinnati, Ohio, USA.
Kleeman
S
S
Doerzbacher
M
M
Lambers
D S
DS
D000653:Amniotic Fluid / Q000187:drug effects / Q000378:metabolism; D001623:Betamethasone / Q000008:administration & dosage*; D005260:Female; D005324:Fetal Movement / Q000187:drug effects*; D005333:Fetus / Q000502:physiology*; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007273:Injections, Intramuscular; D011247:Pregnancy; D012016:Reference Values; D012119:Respiration / Q000187:drug effects*
D005938:Glucocorticoids; D001623:Betamethasone